Veda Halve, Assistant Vice President – Healthcare, Primus Partners, mentions that the next phase of growth for Ayush depends on transitioning from preventive therapy towards an evidence-backed practice integrated into the formal healthcare system. She highlights the need for stronger linkages across primary, secondary and tertiary care, clearly defined referral pathways, standardised treatment protocols and financing mechanisms to improve patient access.
Halve also emphasises that expanding India’s Ayush industry globally will require moving beyond raw materials and product exports towards the export of knowledge and services. Building international confidence in Indian Ayush offerings will depend on robust quality assurance, stronger clinical evidence and standardisation aligned with international benchmarks.
